Literature DB >> 11600399

Staphylococcus aureus mutants selected by BMS-284756.

L F Discotto1, L E Lawrence, K L Denbleyker, J F Barrett.   

Abstract

BMS-284756, a novel des-fluoro(6)-quinolone, was used to select for in vitro mutants of Staphylococcus aureus ISP794. Step mutants were obtained, and the quinolone resistance-determining regions of four target genes, gyrA, gyrB, grlA, and grlB, were sequenced. The data suggest that DNA gyrase is the primary target for BMS-284756 in S. aureus.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11600399      PMCID： PMC90825          DOI： 10.1128/AAC.45.11.3273-3275.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.

Authors:  S Hartman-Neumann; K DenBleyker; L A Pelosi; L E Lawrence; J F Barrett; T J Dougherty
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

3.  Confirmation of protoplast fusion-derived linkages in Staphylococcus aureus by transformation with protoplast DNA.

Authors:  M L Stahl; P A Pattee
Journal:  J Bacteriol       Date:  1983-04       Impact factor: 3.490

4.  Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.

Authors:  H Takahashi; T Kikuchi; S Shoji; S Fujimura; A B Lutfor; Y Tokue; T Nukiwa; A Watanabe
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

5.  Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.

Authors:  M Hosaka; T Yasue; H Fukuda; H Tomizawa; H Aoyama; K Hirai
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191
  6 in total
  9 in total

1.  Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.

Authors:  D E Low; M Muller; C L Duncan; B M Willey; J C de Azavedo; A McGeer; B N Kreiswirth; S Pong-Porter; D J Bast
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

2.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.

Authors:  Laura E Lawrence; MaryBeth Frosco; Brenda Ryan; Susan Chaniewski; Hyekyung Yang; David C Hooper; John F Barrett
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Authors:  Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.

Authors:  Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.

Authors:  Xilin Zhao; William Eisner; Nathan Perl-Rosenthal; Barry Kreiswirth; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

7.  Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.

Authors:  Xiao-Su Pan; Penelope J Hamlyn; Raquel Talens-Visconti; Fabiana L Alovero; Ruben H Manzo; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.

Authors:  Patrick Grohs; Isabelle Podglajen; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.

Authors:  Jijun Cheng; Jane A Thanassi; Christy L Thoma; Barton J Bradbury; Milind Deshpande; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.